Recommendations for cervical cancer prevention in Asia Pacific.
Asia Oceania includes countries from both the Asia Pacific region and Australasia, which cover very diverse geographical areas and populations as well as bearing 52% of the cervical cancer burden in the world. Human papillomavirus (HPV) genotype distribution in women with normal cytology varies between countries in this region, as well as with the distribution typically observed in worldwide estimates or in Western countries. HPV-16 remains the predominant oncogenic type for high-grade cervical dysplasia and cervical cancer across the region, and HPV-18 is generally among the five most common types. HPV-58 is commonly found in cervical cancer as well as in women with normal cytology, and HPV-31, 33 and 35 are relatively less frequent in these regions compared to the West. While screening programmes have been proposed and implemented in several populations, successful programmes are rather limited and the majority of countries still have no or minimal screening services. Prophylactic HPV vaccination will only be feasible when it becomes affordable, thus the current priority and the short-term goal for cervical cancer control is to identify feasible and effective screening measures, and to find the most effective way to combine vaccination with sustainable screening programmes. This Regional Report has carefully described the disease burden of HPV and cervical cancer and the current situations in cervical cancer prevention for many countries in the Asia Oceania region. These data identify the many challenges and opportunities to be considered for policy decisions for cervical cancer control. Furthermore, this report presents the results of advanced decision analytic models calibrated to countries in the region that provide early insight into what strategies are most promising and those likely to be cost-effective and affordable. It thus provides a synthesis of the available evidence-based scientific information, in the context of a significant and systematic international review, that is likely to be useful to governments and public health providers.
Garland
Suzanne M
SM
Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Melbourne, Victoria, Australia. Sue.Garland@the womens.org.au
Cuzick
Jack
J
Domingo
Efren J
EJ
Goldie
Sue J
SJ
Kim
Young-Tak
YT
Konno
Ryo
R
Parkin
D Maxwell
DM
Qiao
You-Lin
YL
Sankaranarayanan
Rengaswamy
R
Stern
Peter L
PL
Tay
Sun Kuie
SK
Bosch
F Xavier
FX
D000293:Adolescent; D000328:Adult; D000368:Aged; D052685:Alphapapillomavirus / Q000145:classification / Q000302:isolation & purification; D001208:Asia / Q000453:epidemiology; D003362:Cost-Benefit Analysis; D005260:Female; D006287:Health Planning Guidelines; D006801:Humans; D017589:Immunization Programs; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D010139:Pacific Islands / Q000453:epidemiology; D030361:Papillomavirus Infections / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000191:economics / Q000592:standards / Q000627:therapeutic use*; D015995:Prevalence; D012307:Risk Factors; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D014611:Vaccination / Q000191:economics / Q000592:standards; D014626:Vaginal Smears; D055815:Young Adult
D053918:Papillomavirus Vaccines